{"id":"bcr-abl","name":"BCR::ABL1 (Philadelphia chromosome)","symbol":"BCR-ABL1","route":"/targets/bcr-abl/","asOf":"2026-09-07","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186716","uniprot":"https://www.uniprot.org/uniprotkb/P11274/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P11274","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5146","open-targets":"https://platform.opentargets.org/target/ENSG00000186716","civic":"https://civicdb.org/genes/613/summary","oncokb":"https://www.oncokb.org/gene/BCR","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BCR","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=BCR","depmap":"https://depmap.org/portal/gene/BCR?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000186716-BCR","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/613","omim":"https://www.omim.org/entry/151410"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000097007","uniprot":"https://www.uniprot.org/uniprotkb/P00519/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P00519","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1862","open-targets":"https://platform.opentargets.org/target/ENSG00000097007","civic":"https://civicdb.org/genes/25/summary","oncokb":"https://www.oncokb.org/gene/ABL1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABL1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=ABL1","depmap":"https://depmap.org/portal/gene/ABL1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000097007-ABL1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/25","omim":"https://www.omim.org/entry/189980"}],"products":[{"id":"asciminib","name":"Asciminib","status":"approved","modality":"Small-molecule allosteric ABL1 inhibitor (STAMP)","route":"/drugs/asciminib/"},{"id":"bosutinib","name":"Bosutinib","status":"approved","modality":"Small-molecule BCR-ABL1/SRC TKI","route":"/drugs/bosutinib/"},{"id":"dasatinib","name":"Dasatinib","status":"approved","modality":"Small-molecule kinase inhibitor (BCR::ABL1, SRC)","route":"/drugs/dasatinib/"},{"id":"flumatinib","name":"Flumatinib","status":"approved","modality":"Oral second-generation BCR-ABL tyrosine kinase inhibitor","route":"/drugs/flumatinib/"},{"id":"nilotinib","name":"Nilotinib","status":"approved","modality":"Small-molecule BCR-ABL1 TKI (second generation)","route":"/drugs/nilotinib/"},{"id":"olverembatinib","name":"Olverembatinib","status":"approved","modality":"Oral third-generation BCR-ABL tyrosine kinase inhibitor","route":"/drugs/olverembatinib/"},{"id":"omacetaxine","name":"Omacetaxine mepesuccinate","status":"approved","modality":"Protein synthesis inhibitor (cephalotaxine ester)","route":"/drugs/omacetaxine/"},{"id":"ponatinib","name":"Ponatinib","status":"approved","modality":"Small-molecule kinase inhibitor (pan-BCR::ABL1 incl. T315I)","route":"/drugs/ponatinib/"}],"trials":[{"id":"nct05456191","name":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","nct":"NCT05456191","phase":"3","status":"active"},{"id":"nct04971226","name":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","nct":"NCT04971226","phase":"3","status":"active"},{"id":"nct02883049","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","nct":"NCT02883049","phase":"3","status":"completed"},{"id":"phallcon","name":"PhALLCON","nct":"NCT03589326","phase":"3","status":"positive"},{"id":"ready-dasatinib","name":"READY","nct":"NCT00744497","phase":"3","status":"negative"},{"id":"dasision","name":"DASISION","nct":"NCT00481247","phase":"3","status":"positive"},{"id":"nct06051409","name":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)","nct":"NCT06051409","phase":"3","status":"recruiting"},{"id":"nct06640361","name":"A Study of Olverembatinib in SDH-deficient GIST.","nct":"NCT06640361","phase":"3","status":"recruiting"},{"id":"nct03784014","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","nct":"NCT03784014","phase":"3","status":"completed"},{"id":"nct04375683","name":"Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL","nct":"NCT04375683","phase":"3"},{"id":"nct06423911","name":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","nct":"NCT06423911","phase":"3","status":"recruiting"},{"id":"d-alba","name":"D-ALBA (GIMEMA LAL2116)","nct":"NCT02744768","phase":"2","status":"positive"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"nct01503502","name":"A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","nct":"NCT01503502","phase":"2"},{"id":"nct05384587","name":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","nct":"NCT05384587","phase":"2","status":"active"},{"id":"nct06514534","name":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","nct":"NCT06514534","phase":"2","status":"recruiting"},{"id":"nct05433532","name":"Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients","nct":"NCT05433532","phase":"2","status":"completed"},{"id":"nct07354074","name":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","nct":"NCT07354074","phase":"2","status":"recruiting"},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","nct":"NCT05725200","phase":"2","status":"recruiting"},{"id":"nct04233346","name":"The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation","nct":"NCT04233346","phase":"2","status":"active"},{"id":"nct06813079","name":"Using Tumor Models to Determine Treatments","nct":"NCT06813079","phase":"2","status":"recruiting"},{"id":"nct07387926","name":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","nct":"NCT07387926","phase":"1/2","status":"recruiting"},{"id":"nct03934372","name":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","nct":"NCT03934372","phase":"1/2","status":"recruiting"},{"id":"nct04501120","name":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","nct":"NCT04501120","phase":"1/2","status":"recruiting"},{"id":"nct04925479","name":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","nct":"NCT04925479","phase":"1/2","status":"recruiting"}],"pathways":["cml-signalling"],"companies":["ascentage-pharma","bms","hansoh-pharma","novartis","pfizer","takeda","teva"],"keyPapers":["paper-iris-imatinib-nejm-2003","paper-druker-imatinib-phase1-nejm-2001"],"hotspots":[{"label":"T315I (gatekeeper)","position":315,"kind":"resistance","drugs":["ponatinib","asciminib"]},{"label":"P-loop (G250E, Y253H, E255K/V)","position":253,"kind":"resistance","drugs":["dasatinib","ponatinib","asciminib"]},{"label":"F317L / V299L","position":317,"kind":"resistance","drugs":["nilotinib","bosutinib","ponatinib"]},{"label":"A337 / P465 / V468 (myristoyl pocket)","position":465,"kind":"resistance","drugs":["ponatinib","dasatinib"]}],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}